Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

59.02 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 59.02
Bid (Size) 59.00 (10)
Ask (Size) 61.20 (1)
Prev. Close 59.02
Today's Range 59.02 - 59.02
52wk Range 50.27 - 67.36
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Stocks Chop As Wall Street Unpacks Powell Comments
Stocks are mixed at midday, as investors weigh remarks from Federal Reserve Chair Jerome Powell. 
Via Talk Markets
Topics Economy
Exposures Interest Rates

Performance

YTD
-9.82%
-9.82%
1 Month
+0.37%
+0.37%
3 Month
+5.71%
+5.71%
6 Month
-9.82%
-9.82%
1 Year
-4.93%
-4.93%

More News

Read More
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Via InvestorPlace
NASDAQ:INCY is not too expensive for the growth it is showing.
Via Chartmill
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
Via Chartmill
Analyst Expectations For Incyte's Future
Via Benzinga
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
Via Chartmill
9 Analysts Have This To Say About Incyte
Via Benzinga
NASDAQ:INCY is showing decent growth, but is still valued reasonably.
Via Chartmill
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers
Via Benzinga
Topics Stocks
Exposures US Equities
Incyte Announces Final Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Announces Preliminary Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Incyte Completes Acquisition of Escient Pharmaceuticals
From Incyte
Via Business Wire
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Via Benzinga
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
From Incyte
Via Business Wire
Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday?
Via Benzinga
Topics Economy
Exposures Interest Rates
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
From Incyte Corporation
Via Business Wire
The 3 Best Biotech Stocks to Buy in May 2024
Via InvestorPlace
NASDAQ:INCY appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.